You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物升近4% RET抑制劑“塞普替尼”正式在中國商業化上市
格隆匯 03-07 10:09
格隆匯3月7日丨信達生物(1801.HK)連升6日,現升3.89%,報44.1港元,總市值677億港元。信達生物3月6日發新聞稿稱,睿妥(塞普替尼)已正式在中國商業化上市。塞普替尼是一種高選擇性和抑制活性的小分子RET抑制劑,由禮來研發,信達生物負責中國商業化。2022年9月,中國國家藥品監督管理局(NMPA)附條件批准塞普替尼在中國用於RET融合陽性的非小細胞肺癌、RET融合陽性的甲狀腺癌、RET突變型甲狀腺髓樣癌(MTC)的治療。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account